Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of tislelizumab + cetuximab + irinotecan in recurrent refractory metastatic colorectal cancer
ChiCTR2000035642Phase 2Completed
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, cetuximab and irinotecan in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Overall response rate. Started Jan 2021; status: completed.
02
Drugs
tislelizumabcetuximabirinotecan
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR2000035642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035642.